A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)

Inclusion Criteria:

• Histologically or cytologically confirmed diagnosis of squamous or nonsquamousnon-small cell lung cancer (NSCLC).

• Measurable disease as assessed by the local site investigator/radiology.

Exclusion Criteria:

• Diagnosis of small cell lung cancer or, for mixed tumors, presence of small cellelements.

• Received prior systemic anticancer therapy for their metastatic NSCLC.

• Known additional malignancy that is progressing or has required active treatmentwithin the past 3 years.

• Known active central nervous system (CNS) metastases and/or carcinomatousmeningitis.

• Active autoimmune disease that has required systemic treatment in the past 2 years.

• History of (noninfectious) pneumonitis/interstitial lung disease that requiredsteroids or has current pneumonitis/interstitial lung disease.

• Active infection requiring systemic therapy.